24/7 Wall Street
26 Sept 2026, 13:30 UTC · 1h ago
Verdict
Headline takes no side. We score KO +0.50 across four claims — strongly bullish.
+0.50strongly bullish
More positive than 70% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish · 0 new · 4 priced in
Johnson & Johnson's Stelara sales fell 59.7% year over year in Q1 due to biosimilar competition.
Priced inanalysis of Q1 results
So whatThe revenue drop must be offset by Darzalex and Tremfya growth to maintain the current FY2026 adj. EPS target of $11.45-$11.65.
More negative than 95% of claims this week
Procter & Gamble forecasts a roughly $1 billion after-tax headwind from commodity, energy, and transportation costs.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
Priced inanalysis of most recent 10-K
So whatThis cost pressure represents ~6.3% of the company's $15.84 billion FY2026 free cash flow, potentially limiting the magnitude of the next dividend raise.
More negative than 85% of claims this week
P&G has planned $10 billion in dividends and $5 billion in buybacks for FY2027.
Priced inmanagement telegraphed plans in recent filing
So whatThe $15 billion total return plan is well-covered by the $15.84 billion FCF generated in FY2026.
More positive than 66% of claims this week
Johnson & Johnson's FY2026 revenue outlook is between $100.3 billion and $101.3 billion.
Priced inmanagement outlook
So whatThis represents a growth target of at least 6.5% over the FY2025 revenue of $94.19 billion.
More positive than 53% of claims this week
Which stocks this story touches
More positive than 70% of ticker scores this week
Highlighted as a 'Dividend King' with a consistent payout history and global market reach.
More positive than 66% of ticker scores this week
Strong cash flow and a 70-year dividend growth streak, though tempered by commodity and tariff headwinds.
More positive than 55% of ticker scores this week
Strong overall financial health and growth in oncology, but facing significant Stelara sales drops and talc litigation.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
1h ago
—
KO hasn't traded since this ran. Last close $87.81 (Sep 25); the reaction starts at the next open.
KO chart →
